Patent ID: 7745415

Claim:
A method of increasing plasma levels of interferon comprising administering to a patient a compound represented by Formula I wherein: R 1a , R 1b , and R 1c are independently H, —C(O)R 3 , a racemic, L-, or D- amino acid group —C(O)CH 2 NHR 4 , —C(O)CH(C 1-6 alkyl)NHR 4 , or R 1b and R 1c are collectively —C(O)—, which together with the oxygen atoms forms a five-membered carbonate ring; R 2 is H; R 3 is a C 1-18 alkyl; and R 4 is H, —C(O)CH(C 1-6 alkyl)NH 2 , or —C(O)CH(CH 2 -aryl)NH 2 ; wherein the alkyl and aryl moieties of the foregoing groups are optionally substituted with substituents independently selected from halo, cyano, nitro, trifluoromethyl, trifluoromethoxy, C 1 -C 6 alkyl, C 2 -C 6 alkenyl, C 2 -C 6 alkynyl, hydroxy, C 1 -C 6 alkoxy, —NH 2 , —NH-alkyl, —N(alkyl) 2 , —NH-aryl, —N(alkyl)(aryl), —N(aryl) 2 , —NHCHO, —NHC(O)alkyl, —NHC(O)aryl, —N(alkyl)C(O)H, —N(alkyl)C(O)alkyl, —N(aryl)C(O)H, —N(aryl)C(O)alkyl, —NHCO 2 alkyl, —N(alkyl)CO 2 alkyl, —NHC(O)NH 2 , —N(alkyl)C(O)NH 2 , —NHC(O)NH-alkyl, —NHC(O)N(alkyl) 2 , —N(alkyl)C(O)NH-alkyl, N(alkyl)C(O)N(alkyl) 2 , —NHSO 2 -alkyl, —N(alkyl)SO 2 -alkyl, —C(O)alkyl, —C(O)aryl, —OC(O)alkyl, —OC(O)aryl, —CO 2 -alkyl, —CO 2 -aryl, —CO 2 H, —C(O)NH 2 , —C(O)NH-alkyl, —C(O)N(alkyl) 2 , —C(O)NH-aryl, —C(O)N(aryl) 2 , —C(O)N(alkyl)(aryl), —S(O)alkyl, —S(O)aryl, —SO 2 alkyl, —SO 2 aryl, —SO 2 NH 2 , —SO 2 NH-alkyl, and —SO 2 N(alkyl) 2 ; or a pharmaceutically acceptable salt thereof.